Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06039215
Other study ID # APHP191098
Secondary ID 2022-A02716-37
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 1, 2023
Est. completion date August 1, 2025

Study information

Verified date September 2023
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute respiratory distress syndrome (ARDS) is a frequent pathology in intensive care (around 10% of patients admitted to intensive care and almost a quarter of patients on mechanical ventilation) and a serious one, with a hospital mortality rate of 40%. The main measures that have an effect on mortality in ARDS involve adjustments to the ventilator, known as protective ventilation. In the most severe patients, adjuvant measures such as prone positioning and the use of curarisation in the initial phase of the disease can improve survival. All these measures have been included in the latest national and international recommendations. However, a vast observational study carried out in 50 countries revealed low compliance with these recommendations. More than a third of patients did not receive protective ventilation, and the majority did not receive prone positioning when this was indicated. During weaning from artificial ventilation, it has been widely demonstrated that replacing clinician judgement with the implementation of paramedical care protocols improved weaning and significantly reduced the duration of artificial ventilation. Therefore, investigators hypothesize that the implementation of a paramedical care protocol for ventilation in the acute phase of ARDS improves compliance with recommendations and thus reduces mortality and the duration of artificial ventilation. However, implementation of such a protocol requires operational training for all the nurses in the participating departments. Simulation appears to be the training method of choice, as it is a teaching technique that enables technical and non-technical skills to be passed on with good retention of what has been learnt, as well as assessing what has been learnt. To make it possible to train several dozen nurses within a tight timescale, a partially dematerialized simulation model incorporating innovative e-learning tools will be developed.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 540
Est. completion date August 1, 2025
Est. primary completion date August 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Intensive care hospitalization; - Intubation with artificial ventilation; - ARDS evolving for less than 72 hours. ARDS criteria according to the Berlin definition, as follows: - Exposure to a risk factor for ARDS or onset/aggravation of pulmonary symptoms within the previous 7 days ; - Respiratory distress not fully explained by cardiac failure or volume overload, with exclusion of hydrostatic edema in the absence of exposure to a risk factor for ARDS; - Hypoxemia with PaO2/FiO2 ratio < 300 mm Hg under PEEP = 5 cmH2O ; - Bilateral opacities on chest X-ray, lung ultrasound or chest CT, not fully explained by pleural effusions, atelectasis or nodules. - Blood pressure monitoring - Affiliation to the social security system. - Written informed consent (patient, relative) or inclusion in emergency situation. Exclusion Criteria: - Long-term oxygen therapy; - Pneumothorax or drained pleurisy; - Documented pulmonary embolism; - Intracranial hypertension; - ARDS refractory to inclusion, i.e.: i) oxygen partial pressure on inspired oxygen fraction a ratio (PaO2/FiO2) <80 mm Hg or plateau pressure (Pplat) > 32 cmH2O despite optimization of mechanical ventilation (tidal volume (Vt) set at 6 mL/kg weight predicted by height, FiO2 =80% and positive expiratory pressure (PEEP) =10 cmH2O) and despite the use of complementary therapies (including prone and/or inhaled nitric oxide); or ii) pH <7. 25 with PaCO2 =60 mm Hg; - ARDS evolving for more than 72 hours with intubation and mechanical ventilation; - Patient deprived of liberty; - Patient under legal protection (guardianship or curatorship); - Known pregnancy or breast-feeding (a pregnancy test will be performed prior to inclusion in patients of childbearing age).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Ventilatory adjustments by nurses
Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.

Locations

Country Name City State
France Assistance Publique-Hôpitaux de Paris service de santé publique Créteil Creteil

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality rate and number of days without mechanical ventilation The primary endpoint will be a combination of mortality and the number of days without mechanical ventilation at D28. This composite criterion will be prioritised so that survival is given priority in the analysis over the shorter duration of mechanical ventilation. 28 days
Secondary Mesure of tidal volume ventilation Up to Day 7
Secondary Mesure of plateau pressure Up to Day 7
Secondary Mesure of positive end-expiratory pressure (PEEP) Up to Day 7
Secondary Mesure of FiO2 Up to Day 7
Secondary Oxygenation arterial blood gases and SpO2 Up to Day 7
Secondary Number of days without mechanical ventilation Up to Day 28
Secondary Number of days without catecholamine Up to Day 28
Secondary Number of days without continuous sedation Up to Day 28
Secondary Duration of mechanical ventilation . from intubation to successful extubation Up to Day 28
Secondary Occurrence of mechanically ventilated pneumothorax Up to Day 28
Secondary Duration of Acute respiratory distress syndrome defined as the day on which the 1st test of spontaneous ventilation was performed UP to Day 28
Secondary Duration of weaning from mechanical ventilation measured as the time between the 1st test of spontaneous ventilation and successful extubation (patient alive and without reintubation within 7 days of extubation). Up to Day 28
Secondary Number of participants with rescue therapy Up to Day 28
Secondary Rate of re-intubation Up to Day 28
Secondary Rate of use of non-invasive ventilation and curative high-flow oxygen therapy Up to Day 28
Secondary Tracheostomy rate Up to Day 28
Secondary Length of stay in intensive care and in hospital. Up to day 28
Secondary Number of deaths in ICU and hospital Up to Day 28
Secondary Number of nurses trained in paramedical protocol per center. Up to 26 months
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Recruiting NCT05535543 - Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
Completed NCT04695392 - Restore Resilience in Critically Ill Children N/A
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Completed NCT04078984 - Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
Completed NCT04451291 - Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure N/A
Not yet recruiting NCT06254313 - The Role of Cxcr4Hi neutrOPhils in InflueNza
Not yet recruiting NCT04798716 - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Phase 1/Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Terminated NCT02867228 - Noninvasive Estimation of Work of Breathing N/A
Not yet recruiting NCT02881385 - Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT01504893 - Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia N/A
Completed NCT02889770 - Dead Space Monitoring With Volumetric Capnography in ARDS Patients N/A
Withdrawn NCT01927237 - Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide N/A
Completed NCT02814994 - Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients N/A
Completed NCT01680783 - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure N/A